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ward	 and	 user‐friendly	 prognostic	 tool	 to	 estimate	 the	 survival	 of	 individual	HCC	
patient	except	for	very	early	stage	patients.
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of	 the	 Liver	 practice	 guidelines,	 the	Barcelona	Clinic	 Liver	Cancer	
(BCLC)	 staging	 system	 is	 the	 currently	 recommended	 staging	 sys‐






function	 in	 the	BCLC	and	many	other	 staging	 systems.2	However,	
there	 are	 some	 shortcomings	 because	 it	 contains	 subjective	 vari‐
ables	such	as	ascites	and	hepatic	encephalopathy	which	often	make	







that	 generates	 numerical	 probabilities	 of	 an	 event.10,11	 Because	













enrolled	 and	 retrospectively	 analysed	 in	 Taipei	 Veterans	 General	
Hospital,	 a	 3000‐bed	 tertiary	 referral	 medical	 centre	 in	 northern	
Taiwan.	The	baseline	demographics,	clinical	information,	PS,	sever‐
ity	of	liver	dysfunction,	serum	biochemistry	and	cancer	staging	were	
comprehensively	 recorded	 at	 the	 time	of	 diagnosis.	 Patients	were	
randomly	 split	 into	 derivation	 and	 validation	 cohort	 by	 1:1	 ratio.	























radiographic	 evidence	 of	 enlarged	 nodes	 (>1	 cm)	 or	 on	 histologi‐
cal	confirmation.	Distant	metastasis	such	as	 lung,	 lymph	node	and	
bone	was	 diagnosed	 by	 CT,	MRI	 or	 bone	 scan.21	 The	 ALBI	 score	
was	 calculated	 according	 to	 the	 following	 equation	 =	 0.66	 ×	 log‐
10bilirubin	 −	 0.085	 ×	 albumin.	 ALBI	 grades	 were	 defined	 as	 ALBI	







































After	 the	diagnosis	was	 confirmed,	patients	were	 reviewed	at	our	
multidisciplinary	HCC	team	for	treatment	recommendation.	Shared	
decision‐making	 regarding	 treatment	modalities	 was	made	 by	 pa‐
tients	 and	 physicians	 after	 individualized	 counselling.	 Written	 in‐
formed	 consent	 was	 obtained	 prior	 to	 any	 definite	 treatment.	




The	Mann‐Whitney	U	 test	was	 used	 to	 compare	 continuous	 vari‐
ables	 between	 two	 groups.	 Category	 data	 were	 assessed	 by	 the	
Chi‐square	 test	 and	 two‐tailed	 Fisher	 exact	 test.	 The	 compari‐
son	 of	 survival	 distribution	 was	 performed	 by	 the	 Kaplan‐Meier	
method	with	 log‐rank	 test.	Multivariate	Cox	proportional	 hazards	
model	was	used	to	determine	 the	BETAs	and	hazard	 ratios	of	 the	
prognostic	 factors	 including	 tumour	 burden,	 ALBI	 grade	 and	 PS.	
Prognostic	 discrimination	 of	 the	 nomogram	model	 was	 examined	
by	the	concordance	 index,	which	provides	the	probability	that	 for	
two	 randomly	 selected	 patients,	 when	 one	 patient	 has	 an	 event	
(death)	 after	 the	 other,	 this	 patient	 has	 a	 better	 outcome	 predic‐









3.1 | Baseline characteristics of patients
The	baseline	characteristics	and	clinical	 information	of	 the	study	
patients	are	summarized	in	Table	2.	A	total	of	3690	patients	were	
included	 for	 analysis.	 Their	 mean	 age	 was	 65	 years	 and	 76%	 of	
patients	were	male.	The	most	common	aetiology	was	hepatitis	B	
(40%)	and	the	majority	of	patients	was	CTP	class	A	(76%).	Patient	
stratification	 according	 to	 the	 ALBI	 grade	 was	 grade	 1	 in	 38%,	
grade	2	in	52%	and	grade	3	in	10%	of	patients.	Regarding	the	tu‐
mour	 status,	 2354	 (64%)	 patients	 presented	with	 single	 tumour,	
and	1619	(44%)	patients	had	tumour	size	greater	than	5	cm.	In	ad‐
dition,	 vascular	 invasion	 or	metastasis	was	 documented	 in	 1034	
(28%)	 of	 patients,	 and	 2186	 (59%)	 of	 patients	were	 classified	 as	
PS	0.	We	re‐staged	the	entire	cohort	according	to	the	ALBI	grade‐
based	BCLC	(ALBI‐BCLC)	system.	A	total	181	(5%),	981	(26%),	621	




3.2 | Treatment and survival analysis
The	 primary	 treatment	 modalities	 for	 both	 derivation	 and	 valida‐
tion	 cohort	 according	 to	 ALBI‐BCLC	 stage	 are	 shown	 in	 Table	 3.	
For	 patients	 with	 ALBI‐BCLC	 stage	 0,	 A,	 B,	 C	 and	 D,	 there	were	
90%,	79%,	44%,	33%	and	15%	of	patients	 in	each	 respective	cat‐
egory	 who	 underwent	 curative	 treatments.	 The	 median	 survival	
of	 the	entire	cohort	was	31	months	 (95%	confidence	 interval	 [CI]:	
28.4‐34.6	months).	The	selection	of	treatment	 in	relation	to	ALBI‐
BCLC	 stage	 and	mortality	 is	 described	 in	 Table	 2.	 There	were	 no	
significant	differences	between	the	derivation	and	validation	cohort	
according	to	treatments	(all	P	>	.05).
The	1‐,	3‐	and	5‐year	survival	 rates	 for	 the	entire	cohort	were	
66%,	47%	and	35%	respectively.	In	the	derivation	cohort,	there	was	
a	 significant	 survival	 difference	 between	 different	 stages	 of	 the	
ALBI‐BCLC	system	 (P	<	 .001,	Figure	1A).	Similarly,	early	 stage	pa‐
tients	of	ALBI‐BCLC	had	better	survival	than	patients	at	advanced	
cancer	stage	in	the	validation	cohort	(P	<	.001,	Figure	1B).
TA B L E  1  Albumin‐bilirubin	(ALBI)	grade‐based	Barcelona	
Clinical	Liver	Cancer	(BCLC)	staging	system
ALBI‐BCLC 0 A B C D
Tumour	burden	
grade
0 1 2 3 Any
ALBI	grade 1 1‐2 1‐2 1‐2 3
Performance	
status
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TA B L E  2  Baseline	characteristics	of	the	derivation	and	validation	cohort




(n = 1844) P
Age	(y,	mean	±	SD) 65	±	13 65	±	13 65	±	13 .776
Male/female	n	(%) 2815/875 (76/24) 1411/435 (76/24) 1404/440 (76/24) .847
Aetiologies	of	liver	disease
HBV,	n	(%) 1475 (40) 741 (40) 732 (40) .993
HCV,	n	(%) 809 (22) 403(22) 406 (22)  
HBV	+	HCV,	(%) 133 (4) 67 (4) 66 (4)  
Others,	(%) 1275 (35) 635 (35) 640 (35)  
Laboratory	values	(mean	±	SD)
Albumin	(g/L) 3.6	±	0.6 3.6	±	0.6 3.6	±	0.6 .320
Bilirubin	(mg/dl) 1.5	±	2.9 1.6	±	3.0 1.5	±	2.6 .588
ALT	(IU/L) 69	±	88 68	±	91 69	±	84 .770
AST	(IU/L) 98	±	207 100	±	250 95	±	151 .399
Creatinine(mg/dl) 1.2	±	1.1 1.2	±	1.2 1.2	±	1.0 .091
Sodium	(mmol/L) 138	±	5 138	±	4 138	±	5 .424
INR	of	PT 1.1	±	0.2 1.1	±	0.2 1.1	±	0.2 .988
Platelet	(1000	UL/L) 172	±	110 174	±	113 170	±	107 .331
AFP	(≧400	ng/mL) 1084 (29) 531 (29) 553 (30) .427
AFP	(ng/mL)	Median	[IQR] 44	[8‐794] 40	[8‐680] 50	[8‐877] .740
Tumour	nodules	(single/multi‐
ple)	n	(%)
2354/1336 (64/36) 1198/648 (65/35) 1156/688 (63/37) .171
Tumour	size	>	5	cm,	n	(%) 1619 (44) 773 (42) 846 (46)  
TTV	median	[IQR] 47	[9‐381] 45	[8.4‐365] 53.6	[10‐448] .796
Vascular	invasion	or	metasta‐
sis,	n	(%)
1034 (28) 526 (29) 508 (28) .533
Ascites,	n	(%) 837(23) 403 (22) 434 (24) .223
DM,	n	(%) 936 (26) 479 (26) 457 (25) .384
CTP	grade	(A/B/C),	n	(%) 2706/812/172 (73/22/5) 1365/395/86 (74/21/5) 1341/417/86 (73/22/5) .668
CTP	score	(mean	±	SD) 6.1	±	1.5 6.0	±	1.5 6.1	±	1.5 .254
ALBI	grade    .191
1 1387 (38) 723 (39) 664 (36)  
2 1927 (52) 931 (51) 996 (54)  
3 376 (10) 192 (10) 184 (10)  
Performance	status    .500
0 2168 (59) 1102 (60) 1066 (58)  
1‐2 1169 (31) 570 (30) 599 (32)  
3‐4 353 (10) 174 (10) 179 (10)  
ALBI‐BCLC	n	(%)    .361
0 181 (5) 101 (5) 80 (4)  
A 981 (26) 504 (27) 477 (26)  
B 621 (17) 306 (17) 315 (17)  
C 1319 (36) 641 (35) 678 (37)  
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Number of patients, median and range of 
follow‐up (mo) and number of confirmed 
mortality
Derivation co‐
hort (n = 1846)
Validation cohort 
(n = 1844) P
ALBI‐based	BCLC	stage	0	(n	=	181,	 
median	=	63	[1‐192],	57)
101 (5) 80 (4) .842
Resection 42 37  
Ablation 48 35  
Transplantation 1 1  
TACE 9 5  
Targeted	therapy 0 0  
Radiotherapy 0 0  
Supportive	care 1 2  
ALBI‐based	BCLC	stage	A	(n	=	981,	 
median	=	47	[1‐242],	485)
504 (27) 477 (26) .165
Resection 229 191  
Ablation 168 181  
Transplantation 1 2  
TACE 102 93  
Targeted	therapy 0 0  
Radiotherapy 0 0  
Supportive	care 4 10  
ALBI‐based	BCLC	stage	B	(n	=	621,	 
median	=	28	[1‐177],	410)
306 (17) 315 (17) .959
Resection 125 123  
Ablation 19 15  
Transplantation 1 1  
TACE 141 151  
Targeted	therapy 6 6  
Radiotherapy 1 1  
Supportive	care 13 18  
ALBI‐based	BCLC	stage	C	(n	=	1319,	 
median	=	10	[1‐165],	955)
641 (35) 678 (37) .734
Resection 133 163  
Ablation 66 78  
Transplantation 1 2  
TACE 226 226  
Targeted	therapy 110 103  
Radiotherapy 9 9  
Supportive	care 96 97  
ALBI‐based	BCLC	stage	D	(n	=	588,	 
median	=	2	[1‐185],	504)
294 (16) 294 (16) .252
Resection 11 15  
Ablation 31 31  
Transplantation 5 3  
TACE 42 52  
Targeted	therapy 31 41  
Radiotherapy 4 9  
Supportive	care 170 143  
Abbreviations:	ALBI,	albumin‐bilirubin;	BCLC,	Barcelona	Clinic	Liver	Cancer;	TACE,	transarterial	
chemoembolization.
TA B L E  3  Treatment	allocation
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F I G U R E  1  A,	Comparison	of	survival	distribution	according	to	albumin‐bilirubin	(ALBI)	grade‐based	Barcelona	Clinic	Liver	Cancer	(BCLC)	
staging	system	in	the	derivation	cohort.	B,	Comparison	of	survival	distribution	according	to	ALBI	grade‐based	BCLC	system	in	the	validation	
cohort.	There	is	significant	survival	difference	between	different	stages	in	both	derivation	and	validation	cohort	(P < .001)
TA B L E  4  Multivariate	survival	analysis	of	patients	in	derivation	cohort	(n	=	1846)
 BETA
BETA × 10/BETA of  





0   1  
Tumour	burden	
grade	1
0.260 1.64 .023 1.297 1.036‐1.623
Tumour	burden	
grade	2
0.718 4.54 <.001 2.051 1.642‐2.561
Tumour	burden	
grade	3
1.579 10 <.001 4.851 3.874‐6.073
ALBI	grade	1 0   1  
ALBI	grade	2 0.665 4.21 <.001 1.944 1.697‐2.227
ALBI	grade	3 1.051 6.66 <.001 2.862 2.323‐3.525
Performance	status	
0
0   1  
Performance	status	
1‐2
0.439 2.78 <.001 1.551 1.356‐1.774
Performance	status	
3‐4
1.084 6.87 <.001 2.957 2.417‐3.618
Abbreviation:	ALBI,	albumin‐bilirubin.
     |  211HO et al.
The	nomogram	was	 constructed	using	BETA	 coefficients	 from	
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3.4 | Discrimination and calibration of nomogram 
in the derivation cohort
The	nomogram	generated	from	the	derivation	cohort	had	a	concord‐







3.5 | Discrimination and calibration of nomogram 
in the validation cohort







The	BCLC	 staging	 system	has	been	 recommended	as	 the	practice	
guideline	 for	 HCC	 in	 both	 Europe	 and	 USA.3,4	 However,	 a	 major	
shortcoming	of	the	BCLC	is	that	the	prognosis	of	patients	within	the	
same	cancer	stage	could	greatly	vary	because	of	highly	variable	clini‐










tion,	whilst	 the	 assessment	 of	 encephalopathy	 can	 be	 challenging	
and	subjective	in	the	CTP	classification.	In	addition,	the	ALBI	score	
is	determined	on	the	basis	of	mathematical	calculation	of	continuous	






































having	 a	 longer	 survival	 is	 about	 77%	 if	 patients	with	 two	 differ‐
ent	nomogram	points	are	selected.	In	comparison	with	our	previous	


























In	 conclusion,	 the	 proposed	 ALBI‐based	 nomogram	 of	 BCLC	
system	for	HCC	is	a	feasible	strategy	in	the	precision	medicine	era.	
Our	data	indicate	that	it	is	a	straightforward,	reproducible	and	user‐
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